A5081947642- Ubiquitin and proteasome pathways
- Cancer-related gene regulation
- CAR-T cell therapy research
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Protein Degradation and Inhibitors
- Cancer Immunotherapy and Biomarkers
- Nanowire Synthesis and Applications
- Biosimilars and Bioanalytical Methods
- Nanofabrication and Lithography Techniques
- Immune Cell Function and Interaction
- 3D Printing in Biomedical Research
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Prostate Cancer Treatment and Research
- Cell Adhesion Molecules Research
- Ferroptosis and cancer prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Glycosylation and Glycoproteins Research
- RNA modifications and cancer
Candiolo Cancer Institute
2018-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2025
Istituto Nazionale Biostrutture e Biosistemi
2018
Abstract Colorectal cancer (CRC) is a heterogeneous disease showing significant variability in clinical aggressiveness and treatment response. Primary acquired resistance limit the efficacy of available treatments, identification new therapeutic targets needed to further improve patients’ outcomes. To identify actionable targets, we performed “drop-out” loss-of-function screening with an shRNA library covering 200 drug-target genes nine different CRC cell lines, whole spectrum molecular...
Colorectal cancer (CRC) is a heterogeneous disease showing significant variability in clinical aggressiveness. Primary and acquired resistance limits the efficacy of available treatments, identification effective drug combinations needed to further improve patients’ outcomes. We previously found that NEDD8-activating enzyme inhibitor pevonedistat induced tumor stabilization preclinical models poorly differentiated, clinically aggressive CRC resistant therapies. To identify drugs can be...
Abstract HER2 amplification occurs in about 5% of colorectal cancers (CRC) and is only partially associated with clinical response to combined HER2/EGFR targeted treatment. An alternative approach, based on Adoptive Cell Therapy (ACT) using T cells engineered anti-HER2 Chimeric Antigen Receptor (CAR), proved toxic due "on-target off-tumor" activity. Therefore, we developed a combinatorial ACT strategy safely target CRC synNotch-based artificial regulatory network. A synthetic Notch receptor...
Colorectal cancer (CRC) is the third most common worldwide, with highly variable prognosis and response to treatment. A large subset of patients does not respond standard treatments or develops resistance. As an alternative, adoptive immunotherapy based on chimeric antigen receptor (CAR)-transduced immune cells has been proposed, however significant adverse events. We therefore evaluated alternative CAR targets already tested in other tumour types employed natural killer cell line NK-92 for...
Abstract Adoptive immunotherapy based on chimeric antigen receptor (CAR)-T cells has led to successful treatment of some hematological malignancies, but it remains extremely challenging for solid tumors, mostly because “on-target off-tumor” toxicity, as observed in the case anti-HER2 CAR-T colorectal cancer (CRC) with HER2 amplification. To enable adoptive against HER2-amplified CRC, we therefore considered a combinatorial strategy synNotch-based artificial regulatory network. A synthetic...
Abstract Currently, the first line therapy for metastatic colorectal cancer (CRC) is FOLFOX regimen, which includes Oxaliplatin in combination with Fluorouracil and Leucovorin. Responses to range from overt regressions (35%) full resistance (25%), eventually all patients become resistant. Indeed, molecular mechanisms of remain mostly be understood. To identify genes involved sensitivity/resistance Oxaliplatin, we designed an integrated approach including forward genetic screens computational...
Abstract Colorectal cancer (CRC) develops and progresses through an accumulation of genetic epigenetic alterations in multiple molecular pathways. Currently, targeted therapies combined with standard chemotherapy are the first-line therapy for metastatic CRC; nevertheless, effectiveness these drugs is limited by primary acquired resistance. Since pathways highly interconnected, development rational combinations can be exploited to circumvent resistance mechanisms. As a possible alternative...
Abstract Colorectal cancer (CRC) is a heterogeneous disease with wide spectrum of clinical outcomes, from indolent resectable to aggressive-metastatic cases. Primary and acquired resistance limits the efficacy available treatments, identification effective drug combinations needed further improve patients' outcomes. We previously found that NEDD8-activating enzyme inhibitor pevonedistat induced tumor stabilization in preclinical models poorly differentiated, clinically aggressive CRC...
<h3>Background</h3> Adoptive immunotherapy based on chimeric antigen receptor (CAR)-T cells has led to successful treatment of different hematological malignancies. However, it remains extremely challenging for solid tumors, mostly because "on-target off-tumour" toxicity, as observed in the case anti-HER2 CAR-T HER2-amplified colorectal cancer (HER2<sub>amp</sub> CRC).<sup>1</sup> To enable adoptive against HER2<sub>amp</sub> CRC, we therefore considered a combinatorial strategy...
Abstract Colorectal cancer (CRC) is a heterogeneous disease with wide spectrum of clinical outcomes, from indolent resectable to aggressive-metastatic cases. Primary and acquired resistance limits the efficacy available treatments, identification effective drug combinations needed further improve patients' outcomes. We previously found that NEDD8-activating enzyme inhibitor pevonedistat induces tumor stabilization in preclinical models poorly differentiated, clinically aggressive CRC...
Colorectal cancer (CRC) is a highly heterogeneous disease, showing significant variability in clinical aggressiveness and treatment response, thus largely hesitating metastatic spread, resistance to therapies unfavorable prognosis. Despite the documented activity of targeted therapies, drugs develops many patients, evaluation more successful combination needed further improve outcomes. NEDD8-activating enzyme inhibitor, Pevonedistat, was previously shown be effective for poorly...